Adagene Inc. (ADAG) - Form 20-F Summary
Business Context and Reporting Period
Company: Adagene Inc.
Reporting Period: Fiscal Year Ended December 31, 2025
Business Overview: Adagene is a clinical-stage biotechnology company focused on developing novel antibody-based cancer immunotherapies. The company utilizes its proprietary Dynamic Precision Library (DPL) platform to power three technologies: NEObody, SAFEbody, and POWERbody. Its lead product candidate is ADG126 (muzastotug), a masked anti-CTLA-4 antibody currently in Phase 1b/2 and Phase 2 clinical trials for metastatic microsatellite-stable (MSS) colorectal cancer. The company is incorporated in the Cayman Islands with substantive operations in China (Suzhou) and the United States.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 (US$) | 2024 (US$) | 2023 (US$) |
|---|---|---|---|
| Revenue | 7,671,000 | 103,000 | 18,111,000 |
| Net Loss | (17,609,000) | (33,424,000) | (18,946,000) |
| Net Loss Per Share (Basic/Diluted) | (0.30) | (0.59) | (0.35) |
| Research & Development Expenses | (22,034,000) | (28,781,000) | (36,639,000) |
| Administrative Expenses | (7,076,000) | (7,274,000) | (8,673,000) |
| Cash and Cash Equivalents (End of Period) | 74,524,000 | 85,195,000 | 109,934,000 |
| Net Cash Used in Operating Activities | (15,657,000) | (29,701,000) | (28,455,000) |
| Accumulated Deficit | (328,785,000) | (311,176,000) | (277,751,000) |
Material Changes vs. Prior Period
- Revenue Surge: Revenue increased significantly to $7.7 million in 2025 from $0.1 million in 2024. This was driven by the recognition of revenue from collaboration agreements with Sanofi (option exercise), ConjugateBio (upfront payment), and Third Arc Bio (upfront payment).
- Reduced Net Loss: Net loss decreased by 47.3% to $17.6 million in 2025 compared to $33.4 million in 2024. This improvement was due to the revenue increase and a 23.4% reduction in R&D expenses as the company prioritized its lead candidate, ADG126.
- R&D Efficiency: R&D expenses declined to $22.0 million in 2025 from $28.8 million in 2024, reflecting a strategic focus on ADG126 and reduced spending on other programs.
- Financing Activity: In July 2025, the company issued Series A non-voting contingently redeemable convertible preferred shares to Sanofi Foreign Participations B.V. for net proceeds of $16.6 million (part of a potential $25.0 million strategic investment).
Guidance, Outlook, and Risks
Outlook and 2026 Objectives:
- Complete enrollment of the randomized Phase 2 dose-optimization study for ADG126 in MSS CRC.
- Provide initial clinical data from a new cohort of patients in the Phase 1b/2 study of ADG126 + pembrolizumab + fruquintinib.
- Share results from the clinical trial collaboration with Roche evaluating ADG126 in hepatocellular carcinoma (HCC).
- Provide preliminary data from an investigator-initiated Phase 2 neoadjuvant trial of ADG126 + pembrolizumab.
Key Risks and Contingencies:
- Regulatory & Delisting Risk: As a Cayman Islands company with operations in China, Adagene faces risks under the Holding Foreign Companies Accountable Act (HFCAA). While the PCAOB currently inspects auditors in China, future inability to do so could lead to delisting from U.S. exchanges.
- Capital Requirements: The company has incurred net losses since inception and expects to continue doing so. It requires substantial additional financing to fund clinical trials and operations. Failure to raise capital could force delays or cessation of programs.
- Clinical Development: Success depends on the safety and efficacy of ADG126. Clinical trials may fail, be delayed, or result in regulatory rejection. The company has no approved products and no revenue from product sales.
- Geopolitical & Data Security: Operations in China are subject to evolving regulations regarding data security, cross-border data transfer, and foreign investment, which could disrupt operations or limit capital raising.
- PFIC Status: The company was likely a Passive Foreign Investment Company (PFIC) for 2025 and may be one for 2026, which could result in adverse U.S. federal income tax consequences for U.S. investors.
Investor Verification Checklist
- Cash Runway: Verify if the $74.5 million cash balance is sufficient to fund operations through the completion of the Phase 2 dose-optimization study and into 2027, given the burn rate.
- ADG126 Clinical Data: Review the specific efficacy and safety data (ORR, PFS, TRAEs) from the Phase 2 dose-optimization study to confirm the "best-in-class" safety profile claims.
- Sanofi Investment Terms: Confirm the conditions for the second closing of the $25.0 million Sanofi investment and the specific clinical milestones required.
- HFCAA Compliance: Monitor PCAOB inspection reports regarding the company's auditor in China to assess ongoing delisting risk.
- Revenue Recognition: Understand the timing of future revenue recognition from the Sanofi, ConjugateBio, and Third Arc agreements, as 2025 revenue was heavily influenced by upfront payments and option exercises.